

Hypoglycemia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/H914EA52BE0EN.html>

Date: July 2020

Pages: 87

Price: US\$ 2,000.00 (Single User License)

ID: H914EA52BE0EN

Abstracts

Hypoglycemia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2020, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Unknown stages are 2, 4, 2, 5 and 2

respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Hypoglycemia - Overview
- Hypoglycemia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hypoglycemia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hypoglycemia - Companies Involved in Therapeutics Development
- Adocia SAS
- AMAG Pharmaceuticals Inc
- Arecor Ltd
- Avolynt Inc
- Eiger BioPharmaceuticals Inc
- LATITUDE Pharmaceuticals Inc
- Rezolute Inc
- Sosei Heptares
- Therakind Ltd
- USV Pvt Ltd
- XERIS Pharmaceuticals Inc
- Zealand Pharma AS
- Zosano Pharma Corp
- Zucara Therapeutics Inc
- Hypoglycemia - Drug Profiles
- avexitide acetate - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- AVO-3235 - Drug Profile
- Product Description
- Mechanism Of Action
- R&D Progress
- dasiglucagon - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypoglycemia, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Hypoglycemia - Pipeline by Adocia SAS, H2 2020
Hypoglycemia - Pipeline by AMAG Pharmaceuticals Inc, H2 2020
Hypoglycemia - Pipeline by Arecor Ltd, H2 2020
Hypoglycemia - Pipeline by Avolynt Inc, H2 2020
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2020
Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2020
Hypoglycemia - Pipeline by Rezolute Inc, H2 2020
Hypoglycemia - Pipeline by Sosei Heptares, H2 2020
Hypoglycemia - Pipeline by Therakind Ltd, H2 2020
Hypoglycemia - Pipeline by USV Pvt Ltd, H2 2020
Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2020
Hypoglycemia - Pipeline by Zealand Pharma AS, H2 2020
Hypoglycemia - Pipeline by Zosano Pharma Corp, H2 2020
Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H2 2020
Hypoglycemia - Dormant Projects, H2 2020
Hypoglycemia - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypoglycemia, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Adocia SAS
AMAG Pharmaceuticals Inc
Arecor Ltd
Avolynt Inc
Eiger BioPharmaceuticals Inc
LATITUDE Pharmaceuticals Inc
Rezolute Inc
Sosei Heptares
Therakind Ltd
USV Pvt Ltd
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Zosano Pharma Corp
Zucara Therapeutics Inc

I would like to order

Product name: Hypoglycemia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/H914EA52BE0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H914EA52BE0EN.html>